- Home
- SNES vs SLXN Comparison
SNES vs SLXN Comparison
Compare SNES & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- SLXN
- Stock Information
- Founded
- SNES 2004
- SLXN 2008
- Country
- SNES United States
- SLXN Israel
- Employees
- SNES N/A
- SLXN N/A
- Industry
- SNES Agricultural Chemicals
- SLXN
- Sector
- SNES Industrials
- SLXN
- Exchange
- SNES Nasdaq
- SLXN NYSE
- Market Cap
- SNES 6.7M
- SLXN 7.3M
- IPO Year
- SNES 2016
- SLXN N/A
- Fundamental
- Price
- SNES $4.80
- SLXN $0.81
- Analyst Decision
- SNES Strong Buy
- SLXN Strong Buy
- Analyst Count
- SNES 1
- SLXN 1
- Target Price
- SNES $10.00
- SLXN $5.00
- AVG Volume (30 Days)
- SNES 228.1K
- SLXN 236.5K
- Earning Date
- SNES 08-07-2025
- SLXN 08-21-2025
- Dividend Yield
- SNES N/A
- SLXN N/A
- EPS Growth
- SNES N/A
- SLXN N/A
- EPS
- SNES N/A
- SLXN N/A
- Revenue
- SNES $1,927,000.00
- SLXN N/A
- Revenue This Year
- SNES $130.53
- SLXN N/A
- Revenue Next Year
- SNES $80.00
- SLXN N/A
- P/E Ratio
- SNES N/A
- SLXN N/A
- Revenue Growth
- SNES 40.15
- SLXN N/A
- 52 Week Low
- SNES $1.30
- SLXN $0.58
- 52 Week High
- SNES $6.48
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- SNES 76.68
- SLXN N/A
- Support Level
- SNES $3.56
- SLXN N/A
- Resistance Level
- SNES $4.46
- SLXN N/A
- Average True Range (ATR)
- SNES 0.38
- SLXN 0.00
- MACD
- SNES 0.10
- SLXN 0.00
- Stochastic Oscillator
- SNES 97.61
- SLXN 0.00
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.